Is Third Time the Charm for Fennec Pharmaceuticals?
Fennec Pharmaceuticals (NASDAQ: FENC), a specialty pharmaceutical company, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for PEDMARK™ (sodium thiosulfate), which was being developed as an intravenous administration for the prevention of ototoxicity...
